A multimodal approach to diabetic macular edema Adrian Au, Rishi P. Singh  Journal of Diabetes and Its Complications  Volume 30, Issue 3, Pages 545-553 (April 2016) DOI: 10.1016/j.jdiacomp.2015.11.008 Copyright © 2016 Elsevier Inc. Terms and Conditions

Fig. 1 A representation of the three various types of anti-VEGF therapy and how they differ in development and mechanism of action. While ranibizumab and bevacizumab are both humanized monoclonal antibodies, ranibizumab has further affinity purification and decreased size. In contrast, aflibercept replicates two portions of the VEGF receptor attached to an antibody Fc region, effectively working as a “trap receptor”. Journal of Diabetes and Its Complications 2016 30, 545-553DOI: (10.1016/j.jdiacomp.2015.11.008) Copyright © 2016 Elsevier Inc. Terms and Conditions

Fig. 2 Mean change in best-corrected visual acuity (BCVA) from baseline through 36months in the RISE/RIDE clinical trials. These outcomes were evaluated by changes in Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Sham subjects that crossed over to the ranibizumab 0.5mg at or after month 25 (n=190) are shown in the transition from the black to red triangles. Journal of Diabetes and Its Complications 2016 30, 545-553DOI: (10.1016/j.jdiacomp.2015.11.008) Copyright © 2016 Elsevier Inc. Terms and Conditions